Abstract 1736P
Background
Young adult lung cancer's socioeconomic and clinical implications make it a unique disease. However, in Bangladesh, the status and features of early-onset lung cancer are not well understood. This study aimed to investigate the socio-demographic status and clinical characteristics of lung cancer in young adults in Bangladesh.
Methods
A retrospective review of patients with lung cancer was performed in our institute from January 2018 and December 2022. Young adults were defined as individuals between 18 and 45 years old. Demographic, clinicopathological and prognostic data were systematically analysed.
Results
Of the 6310 patients, 819 (12.98%) were young adults, and 780 were included in this study. The average age of young adult lung cancer patients was 38.92 years, and the average BMI was 20.46. Of all adult lung cancer patients, 29.49% were female, 58.97% were illiterate, and 87.56% had poor or below-average economic status. Among young adults, 23.08% did not use tobacco, while 41.41% had more than one tobacco-related habit. 33.52% of young patients with right-sided dominant lung cancer had a previous respiratory disease. At the time of presentation, 43.85% of patients had a score of ≥2 on the ECOG scale, and 33.52% had comorbidities, with hypertension being the most frequent (37.36%) and DM (33%) being the second most common. Adenocarcinoma was the most prevalent subtype (58.97%), followed by squamous (24.74%), small cell varieties with undifferentiated (14.74%), and others like sarcoma and mesothelioma. Stage 4 was diagnosed in 28.46% of patients, and the most frequent metastatic site was the lung (14.42%), followed by the pleura (12.5%) and the liver (11.06%). Young lung cancer patients in Bangladesh significantly differed from older adults regarding higher BMI, lower education, more female patients, fewer tobacco users, adenocarcinoma, and different metastatic sites (p 0.05).
Conclusions
The high prevalence of young adult lung cancer in Bangladesh necessitates specialized attention to this vulnerable group during treatment. These patients face unique challenges, making the management of their cancer complex and resulting in poor outcomes. A personalized and comprehensive approach is essential to manage young lung cancer effectively.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1757P - A real-world evaluation of the effectiveness of thermogram along with clinical breast examination in community-based breast cancer screening program
Presenter: Rahul Ravind
Session: Poster session 23
1758P - Body composition meets precision medicine: The prognostic value of sarcopenia in patients (pt) treated with Molecularly Targeted Agents (MTA)
Presenter: Cinta Hierro
Session: Poster session 23
1760P - Systematic review of quality of life (QoL) inclusion among endpoints, reporting and impact of QoL results in phase III non-inferiority trials of systemic treatments in oncology
Presenter: Jessica Paparo
Session: Poster session 23
1761P - Incidence of herpes zoster in cancer patients in Europe: A systematic review
Presenter: Inga Posiuniene
Session: Poster session 23
1762P - Are published data up-to-date? Analysis of time to publication in major oncological journals
Presenter: Pawel Sobczuk
Session: Poster session 23
1763P - The challenge for Cancer Trials Ireland (CTI) to sponsor NCI and non-EU sponsored trials in the EU
Presenter: Eibhlin Mulroe
Session: Poster session 23
1886P - Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Presenter: Craig Gedye
Session: Poster session 23
1887P - Adjuvant everolimus (EVE) in patients (pts) with completely resected very high-risk renal cell cancer (RCC) and clear cell histology: Results from the phase III SWOG S0931 (EVEREST) trial
Presenter: Primo Lara
Session: Poster session 23
1888P - 24-month follow up of durvalumab and savolitinib combination in MET-driven clear cell and non-clear cell renal cancer
Presenter: Francesca Jackson-Spence
Session: Poster session 23